查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1363090

细胞株开发市场规模、份额、趋势分析报告：按产品/服务、按原料、按细胞株类型、按用途、细分趋势，2023-2030

Cell Line Development Market Size, Share & Trends Analysis Report By Product & Services (Reagents And Media, Equipment), By Source (Mammalian, Non-mammalian), By Type of Cell Line, By Source, By Application, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 180 Pages | 商品交期: 2-10个工作天内

价格

细胞株开发市场成长与趋势：

Grand View Research, Inc.最新报告显示，预计到2030年，全球细胞株开发市场规模将达到100.9亿美元，2023年至2030年年复合成长率为9.81%。

推动细胞株开发（CLD）市场扩大的主要要素之一是全球疫苗产量的增加，特别是在冠状病毒传播之后。新医疗保健技术的日益普及和癌症罹患率的上升为 CLD 市场创造了更具吸引力和有利的成长预测。生技药品领域的扩张和成长也预计将成为 CLD 市场开拓的关键决定要素。

市场上越来越多的技术改进的 CLD 治疗方法预计也将推动市场扩张。例如，BICO 子公司 CYTENA 于 2021 年 10 月宣布推出全自动、稳定细胞株开发的新平台。为了提高成本效益并实现更高的实验室自动化，该系统整合CYTENA 一流的液体处理资讯与现有和成熟的单细胞分液技术整合在一起。 BICO 的生物融合议程是透过扩大抗体疗法、基因疗法和生物相似药製造等下一代医疗服务开发的可及性来推动的。

此外，根据 2021 年 7 月的《药品製造更新》，大约 20 种药物预计将于 2023 年专利到期，其中包括诺华 (Novartis) 的 Entresto 和百健 (Biogen) 的 Spinraza 等多种重磅药物。原厂药专利到期催生了生物相似药的诞生。因此，对细胞株开发的需求不断增加。因此，预计它将成为市场成长的驱动力。

此外，联盟、扩张和收购等不断发展的企业策略也推动了市场的成长。例如，ProBioGen 和 Granite Bio 于 2022 年 7 月合作，提供 GMP 製造和细胞株开发解决方案，并支援 Granite Bio 的 mAb 管道开发。同样，2022年6月，FUJIFILM公司宣布将投资16亿美元，用于改善和扩大FUJIFILM Diosynth Biotechnologies的细胞培养产能。此外，2022 年 10 月，Cytiva收购了CEVEC Pharmaceuticals，这是一家先进的 CLD 和病毒载体製造技术的德国着名製造商。透过此次开发，CEVEC将帮助Cytiva保持在生物製造技术领域的领先地位。

然而，建立研发能力所需的高资本成本和支出可能成为细胞株开发产业的障碍。

细胞株开发市场报告亮点

  • 依按产品，试剂和培养基板块占比最大，2022年占43.78%。由于其成本集中和在生技药品生产中的频繁使用，这些产品占据了收益占有率。
  • 它的快速扩张是哺乳动物细胞株有效生产生物製药的结果，因为它们可以表达与人类相同的复杂蛋白质。
  • 依细胞株类型划分，重组细胞株公司细分市场占比最大，2022年占比为31.79%。这是由于它在生技药品製造流程、基因活化、蛋白质相互作用等方面的广泛应用。
  • 从用途来看，生物生产领域占比最大，2022年将达46.30%。体外研究活动的增加、对产品安全性和功效的担忧、对生物相似药的需求以及对细胞疗法的需求不断增长要素正在推动生物生产行业的发展。
  • 2022 年，北美占据了 39.22% 的较大份额，因为不断的技术改进和随后的新发现引发了生物生产新製程的采用。该地区提供高品质 CLD 服务的研究公司的严格活动推动了成长，这些公司包括 Thermo Fisher Scientific Inc.、Sigma-Aldrich Corporation 和美国典型培养物保藏中心 (ATCC)。
  • 市场的主要参与者包括 Thermo Fisher Scientific Inc.、Corning Inc.、Lonza、Creative BioLabs.、WuXi PharmaTech、Sartorius AG、Merck KGaA、Advanced Instruments、Berkeley Lights 和 Danaher。

目录

第1章调查方法和范围

第2章执行摘要

第3章市场变数、趋势和范围

  • 市场体系预测
    • 母市场预测
    • 相关/附随市场预测
  • 市场趋势及展望
  • 市场动态
    • 重磅生技药品专利到期
    • 对单株抗体的需求不断增长
    • 疫苗产量增加
    • 细胞株开发的技术进步
    • 癌症罹患率增加
    • 加大生物科技领域研发投入
  • 市场抑制因素分析
    • 存在复杂的法规结构
  • 营商环境分析
    • PESTEL分析
    • 波特五力分析
    • COVID-19感染疾病的影响分析

第4章按产品/服务分類的业务分析

  • 全球细胞株开发市场：产品与服务的波动分析
  • 试剂和介质
  • 装置
    • 自动化系统
    • 离心机
    • 生物反应器
    • 仓储设备
    • 其他的
  • 配件及消耗品
  • 服务

第5章按来源分類的业务分析

  • 全球细胞株开发市场：来源变异分析
  • 哺乳动物细胞株
  • 非哺乳动物细胞株

第6章按细胞株类型进行业务分析

  • 全球细胞株开发市场：细胞株类型变化分析
  • 重组细胞株
  • 杂交瘤
  • 连续性细胞株
  • 原代细胞株

第7章用途业务分析

  • 全球细胞株开发市场：依用途进行变异分析
  • 生物生产
  • 药物研发
  • 毒性试验
  • 组织工程
  • 其他的

第8章区域业务分析

  • 2022年及2030年全球细胞株开发市场占有率（按地区）
  • 北美洲
    • 北美细胞株开发市场，2018-2030
    • 美国
    • 加拿大
  • 欧洲
    • 欧洲细胞株开发市场，2018-2030
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 亚太细胞株开发市场，2018-2030
    • 日本
    • 中国
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 拉丁美洲细胞株开发市场，2018-2030
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东/非洲
    • MEA细胞株开发市场，2018-2030
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第9章竞争形势

  • 公司分类
  • 策略规划
  • Company Market/PositionShare Analysis, 2022
  • 公司简介/名单
    • Thermo Fisher Scientific Inc.
    • Danaher
    • Merck KGaA
    • Sartorius AG
    • Lonza
    • WuXi PharmaTech
    • Advanced Instruments
    • Berkeley Lights
    • Creative BioLabs
    • Corning Inc.
Product Code: 978-1-68038-481-9

Cell Line Development Market Growth & Trends:

The global cell line development market size is expected to reach USD 10.09 billion by 2030 and is expected to expand at a CAGR of 9.81% from 2023 to 2030, according to a new report by Grand View Research, Inc.. One of the primary factors driving the expansion of the cell line development (CLD) market is an increase in vaccine production around the world, especially after the spread of coronavirus. Rising use of new healthcare technology and rising cancer incidences, create more attractive and lucrative growth prospects for the CLD market. The expansion and growth of the biologics sector will also be a major CLD market development determinant.

The increasing product launches of technologically improved products for CLD are likely to drive market expansion. For example, CYTENA, a BICO subsidiary, introduced a new platform for entirely automated stable cell line development in October 2021. To enable cost-effective and better laboratory automation, the system integrates CYTENA's best-in-class liquid handling information with its existing established single-cell dispensing technology. BICO's Bio Convergence agenda is advanced through the broadening of accessibility to the advancement of next-generation medical services such as antibody treatments, gene therapies, and biosimilar production.

Moreover, according to the July 2021 Pharma Manufacturing Updates, approximately 20 drugs, comprising a few blockbusters including Novartis' Entresto & Biogen's Spinraza, are going to have their patents scheduled to expire in 2023. The expiration of branded pharmaceuticals has resulted in the creation of biosimilars. As a result, the requirement for cell line development is increasing. Thus, it will drive the market growth.

Furthermore, the growing company strategies such as collaboration, expansion, and acquisitions are also driving the market growth. For instance, ProBioGen and Granite Bio collaborated in July 2022 to provide GMP manufacturing & cell line development solutions and support Granite Bio's mAb pipeline development. Similarly, in June 2022, FUJIFILM Corporation announced a USD 1.6 billion investment to improve and expand the cell culture production capabilities of FUJIFILM Diosynth Biotechnologies. Furthermore, in October 2022, Cytiva, acquired CEVEC Pharmaceuticals, a prominent German producer of advanced CLD & viral vector manufacturing technology. Through this development, CEVEC will help Cytiva maintain its leadership position in biomanufacturing technologies.

However, the high capital expenses and expenditure needed to construct research and development capabilities would be a barrier to the cell line development industry.

Cell Line Development Market Report Highlights:

  • By product, the reagents and media segment accounted for the largest share of 43.78% in 2022. Due to their cost-intensive nature and frequent use in the manufacturing of biologics, these items account for the biggest revenue share.
  • By source, the mammalian cell line segment accounted for the largest share of 72.62% in 2022.Its rapid expansion is a result of the effective manufacture of biopharmaceuticals by mammalian cell lines, as they are able to express complex proteins that are identical to those found in humans.
  • By type of cell line, the recombinant cell lines companies segment accounted for the largest share of 31.79% in 2022 due to its widespread application in biologics manufacturing processes, gene activation, including protein interactions.
  • By application, the bioproduction segment held the largest market share of 46.30% in 2022. Factors such as increased in-vitro research activities, product safety and efficacy concerns, the demand for biosimilars, and rising demand for cellular therapies are driving the bioproduction industry.
  • North America held the larger share of 39.22% in 2022 due to the presence of constant technological improvements followed by new discoveries sparking the adoption of newer processes for bioproduction. The presence of rigorous activities carried out by research businesses operating in this region, such as Thermo Fisher Scientific Inc., Sigma-Aldrich Corporation, and American Type Culture Collection (ATCC), which provide high-quality CLD services, is contributing to growth.
  • A few of the key market players of the market include Thermo Fisher Scientific Inc., Corning Inc., Lonza, Creative BioLabs., WuXi PharmaTech, Sartorius AG, Merck KGaA, Advanced Instruments, Berkeley Lights, Danaher among others.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
    • 1.2.1. Information analysis
    • 1.2.2. Market formulation & data visualization
    • 1.2.3. Data validation & publishing
  • 1.3. Information Procurement
    • 1.3.1. Primary Others
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Market Model
  • 1.7. Objectives
    • 1.7.1. Objective 1
    • 1.7.2. Objective 2

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Trends and Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Patent expiration of blockbuster biologics
    • 3.3.2. Rising demand for monoclonal antibodies
    • 3.3.3. Increasing vaccine production
    • 3.3.4. Technological advancement for the cell line development
    • 3.3.5. Increasing prevalence of cancer
    • 3.3.6. Growing R&D investments in biotechnology sector
  • 3.4. Market Restraint Analysis
    • 3.4.1. Presence of complicated regulatory framework
  • 3.5. Business Environment Analysis
    • 3.5.1. PESTEL Analysis
    • 3.5.2. Porter's Five Forces Analysis
    • 3.5.3. COVID-19 Impact Analysis

Chapter 4. Product & Services Business Analysis

  • 4.1. Global cell line development market: Product & Services Movement Analysis
  • 4.2. Reagents and media
    • 4.2.1. Reagents and media Market, 2018 - 2030 (USD Million)
  • 4.3. Equipment
    • 4.3.1. Equipment Market, 2018 - 2030 (USD Million)
    • 4.3.2. Automated Systems
      • 4.3.2.1. Automated Systems Market, 2018 - 2030 (USD Million)
    • 4.3.3. Centrifuges
      • 4.3.3.1. Centrifuges Market, 2018 - 2030 (USD Million)
    • 4.3.4. Bioreactors
      • 4.3.4.1. Bioreactors Market, 2018 - 2030 (USD Million)
    • 4.3.5. Storage equipment
      • 4.3.5.1. Storage equipment Market, 2018 - 2030 (USD Million)
    • 4.3.6. Others
      • 4.3.6.1. Others Market, 2018 - 2030 (USD Million)
  • 4.4. Accessories and consumables
    • 4.4.1. Accessories and consumables Market, 2018 - 2030 (USD Million)
  • 4.5. Services
    • 4.5.1. Services Market, 2018 - 2030 (USD Million)

Chapter 5. Source Business Analysis

  • 5.1. Global cell line development market: Source Movement Analysis
  • 5.2. Mammalian cell line
    • 5.2.1. Mammalian cell line Market, 2018 - 2030 (USD Million)
  • 5.3. Non-mammalian cell line
    • 5.3.1. Non-mammalian cell line Market, 2018 - 2030 (USD Million)
    • 5.3.2. Insects
      • 5.3.2.1. Insects Market, 2018 - 2030 (USD Million)
    • 5.3.3. Amphibians
      • 5.3.3.1. Amphibians Market, 2018 - 2030 (USD Million)

Chapter 6. Type of Cell Lines Business Analysis

  • 6.1. Global cell line development market: Type of Cell Lines Movement Analysis
  • 6.2. Recombinant cell lines
    • 6.2.1. Recombinant cell lines Market, 2018 - 2030 (USD Million)
  • 6.3. Hybridomas
    • 6.3.1. Hybridomas Market, 2018 - 2030 (USD Million)
  • 6.4. Continuous cell lines
    • 6.4.1. Continuous cell lines Market, 2018 - 2030 (USD Million)
  • 6.5. Primary cell lines
    • 6.5.1. Primary cell lines Market, 2018 - 2030 (USD Million)

Chapter 7. Application Business Analysis

  • 7.1. Global cell line development market: Application Movement Analysis
  • 7.2. Bioproduction
    • 7.2.1. Bioproduction Market, 2018 - 2030 (USD Million)
  • 7.3. Drug discovery
    • 7.3.1. Drug discovery Market, 2018 - 2030 (USD Million)
  • 7.4. Toxicity testing
    • 7.4.1. Toxicity testing Market, 2018 - 2030 (USD Million)
  • 7.5. Tissue engineering
    • 7.5.1. Tissue engineering Market, 2018 - 2030 (USD Million)
  • 7.6. Others
    • 7.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 8. Regional Business Analysis

  • 8.1. Global Cell line development market Share By Region, 2022 & 2030
  • 8.2. North America
    • 8.2.1. North America cell line development market, 2018 - 2030 (USD Million)
    • 8.2.2. U.S.
      • 8.2.2.1. Key Country Dynamics
      • 8.2.2.2. Competitive Scenario
      • 8.2.2.3. Regulatory Framework
      • 8.2.2.4. Target Disease Prevalence
      • 8.2.2.5. U.S. cell line development market, 2018 - 2030 (USD Million)
    • 8.2.3. Canada
      • 8.2.3.1. Key Country Dynamics
      • 8.2.3.2. Competitive Scenario
      • 8.2.3.3. Regulatory Framework
      • 8.2.3.4. Target Disease Prevalence
      • 8.2.3.5. Canada cell line development market, 2018 - 2030 (USD Million)
  • 8.3. Europe
    • 8.3.1. Europe Cell line development market, 2018 - 2030 (USD Million)
    • 8.3.2. Germany
      • 8.3.2.1. Key Country Dynamics
      • 8.3.2.2. Competitive Scenario
      • 8.3.2.3. Regulatory Framework
      • 8.3.2.4. Target Disease Prevalence
      • 8.3.2.5. Germany cell line development market, 2018 - 2030 (USD Million)
    • 8.3.3. UK
      • 8.3.3.1. Key Country Dynamics
      • 8.3.3.2. Competitive Scenario
      • 8.3.3.3. Regulatory Framework
      • 8.3.3.4. Target Disease Prevalence
      • 8.3.3.5. UK cell line development market, 2018 - 2030 (USD Million)
    • 8.3.4. France
      • 8.3.4.1. Key Country Dynamics
      • 8.3.4.2. Competitive Scenario
      • 8.3.4.3. Regulatory Framework
      • 8.3.4.4. Target Disease Prevalence
      • 8.3.4.5. France cell line development market, 2018 - 2030 (USD Million)
    • 8.3.5. Italy
      • 8.3.5.1. Key Country Dynamics
      • 8.3.5.2. Competitive Scenario
      • 8.3.5.3. Regulatory Framework
      • 8.3.5.4. Target Disease Prevalence
      • 8.3.5.5. Italy cell line development market, 2018 - 2030 (USD Million)
    • 8.3.6. Spain
      • 8.3.6.1. Key Country Dynamics
      • 8.3.6.2. Competitive Scenario
      • 8.3.6.3. Regulatory Framework
      • 8.3.6.4. Target Disease Prevalence
      • 8.3.6.5. Spain cell line development market, 2018 - 2030 (USD Million)
    • 8.3.7. Denmark
      • 8.3.7.1. Key Country Dynamics
      • 8.3.7.2. Competitive Scenario
      • 8.3.7.3. Regulatory Framework
      • 8.3.7.4. Target Disease Prevalence
      • 8.3.7.5. Denmark cell line development market, 2018 - 2030 (USD Million)
    • 8.3.8. Sweden
      • 8.3.8.1. Key Country Dynamics
      • 8.3.8.2. Competitive Scenario
      • 8.3.8.3. Regulatory Framework
      • 8.3.8.4. Target Disease Prevalence
      • 8.3.8.5. Sweden cell line development market, 2018 - 2030 (USD Million)
    • 8.3.9. Norway
      • 8.3.9.1. Key Country Dynamics
      • 8.3.9.2. Competitive Scenario
      • 8.3.9.3. Regulatory Framework
      • 8.3.9.4. Target Disease Prevalence
      • 8.3.9.5. Norway cell line development market, 2018 - 2030 (USD Million)
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific cell line development market, 2018 - 2030 (USD Million)
    • 8.4.2. Japan
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Competitive Scenario
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. Target Disease Prevalence
      • 8.4.2.5. Japan cell line development market, 2018 - 2030 (USD Million)
    • 8.4.3. China
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Competitive Scenario
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. Target Disease Prevalence
      • 8.4.3.5. China cell line development market, 2018 - 2030 (USD Million)
    • 8.4.4. India
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Competitive Scenario
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. Target Disease Prevalence
      • 8.4.4.5. India cell line development market, 2018 - 2030 (USD Million)
    • 8.4.5. South Korea
      • 8.4.5.1. Key Country Dynamics
      • 8.4.5.2. Competitive Scenario
      • 8.4.5.3. Regulatory Framework
      • 8.4.5.4. Target Disease Prevalence
      • 8.4.5.5. South Korea cell line development market, 2018 - 2030 (USD Million)
    • 8.4.6. Australia
      • 8.4.6.1. Key Country Dynamics
      • 8.4.6.2. Competitive Scenario
      • 8.4.6.3. Regulatory Framework
      • 8.4.6.4. Target Disease Prevalence
      • 8.4.6.5. Australia cell line development market, 2018 - 2030 (USD Million)
    • 8.4.7. Thailand
      • 8.4.7.1. Key Country Dynamics
      • 8.4.7.2. Competitive Scenario
      • 8.4.7.3. Regulatory Framework
      • 8.4.7.4. Target Disease Prevalence
      • 8.4.7.5. Thailand cell line development market, 2018 - 2030 (USD Million)
  • 8.5. Latin America
    • 8.5.1. Latin America cell line development market, 2018 - 2030 (USD Million)
    • 8.5.2. Brazil
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Competitive Scenario
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. Target Disease Prevalence
      • 8.5.2.5. Brazil cell line development market, 2018 - 2030 (USD Million)
    • 8.5.3. Mexico
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Competitive Scenario
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. Target Disease Prevalence
      • 8.5.3.5. Mexico cell line development market, 2018 - 2030 (USD Million)
    • 8.5.4. Argentina
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Competitive Scenario
      • 8.5.4.3. Regulatory Framework
      • 8.5.4.4. Target Disease Prevalence
      • 8.5.4.5. Argentina cell line development market, 2018 - 2030 (USD Million)
  • 8.6. MEA
    • 8.6.1. MEA cell line development market, 2018 - 2030 (USD Million)
    • 8.6.2. South Africa
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Competitive Scenario
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. Target Disease Prevalence
      • 8.6.2.5. South Africa cell line development market, 2018 - 2030 (USD Million)
    • 8.6.3. Saudi Arabia
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Competitive Scenario
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. Target Disease Prevalence
      • 8.6.3.5. Saudi Arabia cell line development market, 2018 - 2030 (USD Million)
    • 8.6.4. UAE
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Competitive Scenario
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. Target Disease Prevalence
      • 8.6.4.5. UAE cell line development market, 2018 - 2030 (USD Million)
    • 8.6.5. Kuwait
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Competitive Scenario
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. Target Disease Prevalence
      • 8.6.5.5. Kuwait cell line development market, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Company Categorization
  • 9.2. Strategy Mapping
  • 9.3. Company Market/PositionShare Analysis, 2022
  • 9.4. Company Profiles/Listing
    • 9.4.1. Thermo Fisher Scientific Inc.
      • 9.4.1.1. Overview
      • 9.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.1.3. Product Benchmarking
      • 9.4.1.4. Strategic Initiatives
    • 9.4.2. Danaher
      • 9.4.2.1. Overview
      • 9.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.2.3. Product Benchmarking
      • 9.4.2.4. Strategic Initiatives
    • 9.4.3. Merck KGaA
      • 9.4.3.1. Overview
      • 9.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.3.3. Product Benchmarking
      • 9.4.3.4. Strategic Initiatives
    • 9.4.4. Sartorius AG
      • 9.4.4.1. Overview
      • 9.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.4.3. Product Benchmarking
      • 9.4.4.4. Strategic Initiatives
    • 9.4.5. Lonza
      • 9.4.5.1. Overview
      • 9.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.5.3. Product Benchmarking
      • 9.4.5.4. Strategic Initiatives
    • 9.4.6. WuXi PharmaTech
      • 9.4.6.1. Overview
      • 9.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.6.3. Product Benchmarking
      • 9.4.6.4. Strategic Initiatives
    • 9.4.7. Advanced Instruments
      • 9.4.7.1. Overview
      • 9.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.7.3. Product Benchmarking
      • 9.4.7.4. Strategic Initiatives
    • 9.4.8. Berkeley Lights
      • 9.4.8.1. Overview
      • 9.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.8.3. Product Benchmarking
      • 9.4.8.4. Strategic Initiatives
    • 9.4.9. Creative BioLabs
      • 9.4.9.1. Overview
      • 9.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.9.3. Product Benchmarking
      • 9.4.9.4. Strategic Initiatives
    • 9.4.10. Corning Inc.
      • 9.4.10.1. Overview
      • 9.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.10.3. Product Benchmarking
      • 9.4.10.4. Strategic Initiatives

List of Tables

  • Table 1 List Of Secondary Sources
  • Table 2 List Of Abbreviations
  • Table 3 Global Cell line development market by Product & Services, 2018 - 2030 (USD Million)
  • Table 4 Global Cell line development market by Source, 2018 - 2030 (USD Million)
  • Table 5 Global Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
  • Table 6 Global Cell line development market by Application, 2018 - 2030 (USD Million)
  • Table 7 North America Cell line development market by Product & Services, 2018 - 2030 (USD Million)
  • Table 8 North America Cell line development market by Source, 2018 - 2030 (USD Million)
  • Table 9 North America Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
  • Table 10 North America Cell line development market by Application, 2018 - 2030 (USD Million)
  • Table 11 North America Cell line development market by Country, 2018 - 2030 (USD Million)
  • Table 12 U.S. Cell line development market by Product & Services, 2018 - 2030 (USD Million)
  • Table 13 U.S. Cell line development market by Source, 2018 - 2030 (USD Million)
  • Table 14 U.S. Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
  • Table 15 U.S. Cell line development market by Application, 2018 - 2030 (USD Million)
  • Table 16 Canada Cell line development market by Source, 2018 - 2030 (USD Million)
  • Table 17 Canada Cell line development market by Source, 2018 - 2030 (USD Million)
  • Table 18 Canada Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
  • Table 19 Canada Cell line development market by Application, 2018 - 2030 (USD Million)
  • Table 20 Europe Cell line development market by Product & Services, 2018 - 2030 (USD Million)
  • Table 21 Europe Cell line development market by Source, 2018 - 2030 (USD Million)
  • Table 22 Europe Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
  • Table 23 Europe Cell line development market by Application, 2018 - 2030 (USD Million)
  • Table 24 Europe Cell line development market by Country, 2018 - 2030 (USD Million)
  • Table 25 UK Cell line development market by Product & Services, 2018 - 2030 (USD Million)
  • Table 26 UK Cell line development market by Source, 2018 - 2030 (USD Million)
  • Table 27 UK Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
  • Table 28 UK Cell line development market by Application, 2018 - 2030 (USD Million)
  • Table 29 Germany Cell line development market by Product & Services, 2018 - 2030 (USD Million)
  • Table 30 Germany Cell line development market by Source, 2018 - 2030 (USD Million)
  • Table 31 Germany Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
  • Table 32 Germany Cell line development market by Application, 2018 - 2030 (USD Million)
  • Table 33 France Cell line development market by Product & Services, 2018 - 2030 (USD Million)
  • Table 34 France Cell line development market by Source, 2018 - 2030 (USD Million)
  • Table 35 France Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
  • Table 36 France Cell line development market by Application, 2018 - 2030 (USD Million)
  • Table 37 Italy Cell line development market by Product & Services, 2018 - 2030 (USD Million)
  • Table 38 Italy Cell line development market by Source, 2018 - 2030 (USD Million)
  • Table 39 Italy Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
  • Table 40 Italy Cell line development market by Application, 2018 - 2030 (USD Million)
  • Table 41 Spain Cell line development market by Product & Services, 2018 - 2030 (USD Million)
  • Table 42 Spain Cell line development market by Source, 2018 - 2030 (USD Million)
  • Table 43 Spain Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
  • Table 44 Spain Cell line development market by Application, 2018 - 2030 (USD Million)
  • Table 45 Denmark Cell line development market by Product & Services, 2018 - 2030 (USD Million)
  • Table 46 Denmark Cell line development market by Source, 2018 - 2030 (USD Million)
  • Table 47 Denmark Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
  • Table 48 Denmark Cell line development market by Application, 2018 - 2030 (USD Million)
  • Table 49 Sweden Cell line development market by Product & Services, 2018 - 2030 (USD Million)
  • Table 50 Sweden Cell line development market by Source, 2018 - 2030 (USD Million)
  • Table 51 Sweden Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
  • Table 52 Sweden Cell line development market by Application, 2018 - 2030 (USD Million)
  • Table 53 Norway Cell line development market by Product & Services, 2018 - 2030 (USD Million)
  • Table 54 Norway Cell line development market by Source, 2018 - 2030 (USD Million)
  • Table 55 Norway Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
  • Table 56 Norway Cell line development market by Application, 2018 - 2030 (USD Million)
  • Table 57 Asia Pacific Cell line development market by Product & Services, 2018 - 2030 (USD Million)
  • Table 58 Asia Pacific Cell line development market by Source, 2018 - 2030 (USD Million)
  • Table 59 Asia Pacific Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
  • Table 60 Asia Pacific Cell line development market by Application, 2018 - 2030 (USD Million)
  • Table 61 Asia Pacific Cell line development market by Country, 2018 - 2030 (USD Million)
  • Table 62 China Cell line development market by Product & Services, 2018 - 2030 (USD Million)
  • Table 63 China Cell line development market by Source, 2018 - 2030 (USD Million)
  • Table 64 China Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
  • Table 65 China Cell line development market by Application, 2018 - 2030 (USD Million)
  • Table 66 Japan Cell line development market by Product & Services, 2018 - 2030 (USD Million)
  • Table 67 Japan Cell line development market by Source, 2018 - 2030 (USD Million)
  • Table 68 Japan Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
  • Table 69 Japan Cell line development market by Application, 2018 - 2030 (USD Million)
  • Table 70 India Cell line development market by Product & Services, 2018 - 2030 (USD Million)
  • Table 71 India Cell line development market by Source, 2018 - 2030 (USD Million)
  • Table 72 India Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
  • Table 73 India Cell line development market by Application, 2018 - 2030 (USD Million)
  • Table 74 South Korea Cell line development market by Product & Services, 2018 - 2030 (USD Million)
  • Table 75 South Korea Cell line development market by Source, 2018 - 2030 (USD Million)
  • Table 76 South Korea Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
  • Table 77 South Korea Cell line development market by Application, 2018 - 2030 (USD Million)
  • Table 78 Australia Cell line development market by Product & Services, 2018 - 2030 (USD Million)
  • Table 79 Australia Cell line development market by Source, 2018 - 2030 (USD Million)
  • Table 80 Australia Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
  • Table 81 Australia Cell line development market by Application, 2018 - 2030 (USD Million)
  • Table 82 Thailand Cell line development market by Product & Services, 2018 - 2030 (USD Million)
  • Table 83 Thailand Cell line development market by Source, 2018 - 2030 (USD Million)
  • Table 84 Thailand Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
  • Table 85 Thailand Cell line development market by Application, 2018 - 2030 (USD Million)
  • Table 86 Latin America Cell line development market by Product & Services, 2018 - 2030 (USD Million)
  • Table 87 Latin America Cell line development market by Source, 2018 - 2030 (USD Million)
  • Table 88 Latin America Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
  • Table 89 Latin America Cell line development market by Application, 2018 - 2030 (USD Million)
  • Table 90 Latin America Cell line development market by Country, 2018 - 2030 (USD Million)
  • Table 91 Brazil Cell line development market by Product & Services, 2018 - 2030 (USD Million)
  • Table 92 Brazil Cell line development market by Source, 2018 - 2030 (USD Million)
  • Table 93 Brazil Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
  • Table 94 Brazil Cell line development market by Application, 2018 - 2030 (USD Million)
  • Table 95 Mexico Cell line development market by Product & Services, 2018 - 2030 (USD Million)
  • Table 96 Mexico Cell line development market by Source, 2018 - 2030 (USD Million)
  • Table 97 Mexico Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
  • Table 98 Mexico Cell line development market by Application, 2018 - 2030 (USD Million)
  • Table 99 Argentina Cell line development market by Product & Services, 2018 - 2030 (USD Million)
  • Table 100 Argentina Cell line development market by Source, 2018 - 2030 (USD Million)
  • Table 101 Argentina Cell line development market by Type of Cell Liner, 2018 - 2030 (USD Million)
  • Table 102 Argentina Cell line development market by Application, 2018 - 2030 (USD Million)
  • Table 103 Middle East & Africa Cell line development market by Product & Services, 2018 - 2030 (USD Million)
  • Table 104 Middle East & Africa Cell line development market by Source, 2018 - 2030 (USD Million)
  • Table 105 Middle East & Africa Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
  • Table 106 Middle East & Africa Cell line development market by Application, 2018 - 2030 (USD Million)
  • Table 107 Middle East & Africa Cell line development market by Country, 2018 - 2030 (USD Million)
  • Table 108 South Africa Cell line development market by Product & Services, 2018 - 2030 (USD Million)
  • Table 109 South Africa Cell line development market by Source, 2018 - 2030 (USD Million)
  • Table 110 South Africa Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
  • Table 111 South Africa Cell line development market by Application, 2018 - 2030 (USD Million)
  • Table 112 Saudi Arabia Cell line development market by Product & Services, 2018 - 2030 (USD Million)
  • Table 113 Saudi Arabia Cell line development market by Source, 2018 - 2030 (USD Million)
  • Table 114 Saudi Arabia Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
  • Table 115 Saudi Arabia Cell line development market by Application, 2018 - 2030 (USD Million)
  • Table 116 UAE Cell line development market by Product & Services, 2018 - 2030 (USD Million)
  • Table 117 UAE Cell line development market by Source, 2018 - 2030 (USD Million)
  • Table 118 UAE Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
  • Table 119 UAE Cell line development market by Application, 2018 - 2030 (USD Million)
  • Table 120 Kuwait Cell line development market by Product & Services, 2018 - 2030 (USD Million)
  • Table 121 Kuwait Cell line development market by Source, 2018 - 2030 (USD Million)
  • Table 122 Kuwait Cell line development market By Type of Cell Line, 2018 - 2030 (USD Million)
  • Table 123 Kuwait Cell line development market by Application, 2018 - 2030 (USD Million)
  • Table 124 Participant's Overview
  • Table 125 Financial Performance
  • Table 126 Key Companies Undergoing Expansions
  • Table 127 Key Companies Undergoing Acquisitions
  • Table 128 Key Companies Undergoing Collaborations
  • Table 129 Key Companies Launching New Products/Services
  • Table 130 Key Companies Undergoing Partnerships
  • Table 131 Key Companies Undertaking Other Strategies

List of Figures

  • Fig. 1 Market Others process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary Others pattern
  • Fig. 4 Market Others approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market summary, 2022 (USD Million)
  • Fig. 9 Market segmentation & scope
  • Fig. 10 Market driver impact
  • Fig. 11 Market restraint impact
  • Fig. 12 Penetration & growth prospect mapping
  • Fig. 13 Porter's analysis
  • Fig. 14 SWOT analysis
  • Fig. 15 Global cell line development market: Product & services outlook and key takeaways
  • Fig. 16 Global cell line development market: Product & services movement analysis
  • Fig. 17 Global reagents and media market, 2018 - 2030 (USD Million)
  • Fig. 18 Global equipment market, 2018 - 2030 (USD Million)
  • Fig. 19 Global Automated Systems market, 2018 - 2030 (USD Million)
  • Fig. 20 Global centrifuges market, 2018 - 2030 (USD Million)
  • Fig. 21 Global bioreactors market, 2018 - 2030 (USD Million)
  • Fig. 22 Global storage equipment market, 2018 - 2030 (USD Million)
  • Fig. 23 Global Others market, 2018 - 2030 (USD Million)
  • Fig. 24 Global Accessories and consumables market, 2018 - 2030 (USD Million)
  • Fig. 25 Global cell line development market: Source outlook and key takeaways
  • Fig. 26 Global cell line development market: Source movement analysis
  • Fig. 27 Global mammalian cell line market, 2018 - 2030 (USD Million)
  • Fig. 28 Global non-mammalian cell line market, 2018 - 2030 (USD Million)
  • Fig. 29 Global insects market, 2018 - 2030 (USD Million)
  • Fig. 30 Global amphibians market, 2018 - 2030 (USD Million)
  • Fig. 31 Global cell line development market: Type of cell line outlook and key takeaways
  • Fig. 32 Global cell line development market: Type of cell line movement analysis
  • Fig. 33 Global recombinant cell lines market, 2018 - 2030 (USD Million)
  • Fig. 34 Global hybridomas market, 2018 - 2030 (USD Million)
  • Fig. 35 Global continuous cell lines market, 2018 - 2030 (USD Million)
  • Fig. 36 Global primary cell lines market, 2018 - 2030 (USD Million)
  • Fig. 37 Global cell line development market: Application outlook and key takeaways
  • Fig. 38 Global cell line development market: Application movement analysis
  • Fig. 39 Global bioproduction market, 2018 - 2030 (USD Million)
  • Fig. 40 Global drug discovery market, 2018 - 2030 (USD Million)
  • Fig. 41 Global toxicity testing market, 2018 - 2030 (USD Million)
  • Fig. 42 Global tissue engineering market, 2018 - 2030 (USD Million)
  • Fig. 43 Global Others market, 2018 - 2030 (USD Million)
  • Fig. 44 Global cell line development market: Regional outlook and key takeaways
  • Fig. 45 North America cell line development market, 2018 - 2030 (USD Million)
  • Fig. 46 U.S. key country dynamics
  • Fig. 47 U.S. cell line development market, 2018 - 2030 (USD Million)
  • Fig. 48 Canada key country dynamics
  • Fig. 49 Canada cell line development market, 2018 - 2030 (USD Million)
  • Fig. 50 Europe cell line development market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 51 Germany key country dynamics
  • Fig. 52 Germany cell line development market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 53 France key country dynamics
  • Fig. 54 France cell line development market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 55 UK key country dynamics
  • Fig. 56 UK cell line development market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 57 Italy key country dynamics
  • Fig. 58 Italy cell line development market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 59 Spain key country dynamics
  • Fig. 60 Spain cell line development market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 61 Denmark key country dynamics
  • Fig. 62 Denmark cell line development market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 63 Sweden key country dynamics
  • Fig. 64 Sweden cell line development market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 65 Norway key country dynamics
  • Fig. 66 Norway cell line development market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 67 Asia-Pacific cell line development market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 68 China key country dynamics
  • Fig. 69 China cell line development market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 70 India key country dynamics
  • Fig. 71 India cell line development market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 72 South Korea key country dynamics
  • Fig. 73 South Korea cell line development market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 74 Japan key country dynamics
  • Fig. 75 Japan cell line development market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 76 Australia key country dynamics
  • Fig. 77 Australia cell line development market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 78 Thailand key country dynamics
  • Fig. 79 Thailand cell line development market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 80 Latin America cell line development market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 81 Brazil key country dynamics
  • Fig. 82 Brazil cell line development market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 83 Mexico key country dynamics
  • Fig. 84 Mexico cell line development market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 85 Argentina key country dynamics
  • Fig. 86 Argentina cell line development market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 87 MEA cell line development market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 88 South Africa key country dynamics
  • Fig. 89 South Africa cell line development market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 90 Saudi Arabia key country dynamics
  • Fig. 91 Saudi Arabia cell line development market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 92 UAE key country dynamics
  • Fig. 93 UAE cell line development market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 94 Kuwait key country dynamics
  • Fig. 95 Kuwait cell line development market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 96 Market participant categorization
  • Fig. 97 Cell line development market share analysis, 2022
  • Fig. 98 Strategy framework